ArticlePloS one2014
Characterization of Scedosporium apiospermum glucosylceramides and their involvement in fungal development and macrophage functions.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Early inflammatory macrophage reprogramming byVirulence · 2026Article
- Impact of Copper(II) and Silver(I) Complexes Containing 1,10-phenanthroline-5,6-dione on Cellular and Virulence Aspects ofCurrent topics in medicinal chemistry · 2025Article
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
- Extracellular Vesicles fromJournal of fungi (Basel, Switzerland) · 2024Article
- Deciphering the Role of PIG1 and DHN-Melanin inJournal of fungi (Basel, Switzerland) · 2023Article
- Biochemical and structural studies of target lectin SapL1 from the emerging opportunistic microfungus Scedosporium apiospermum.Scientific reports · 2021Article
- Miltefosine AgainstFrontiers in cellular and infection microbiology · 2021Article
- Glucosylceramide Plays a Role in Fungal Germination, Lipid Raft Organization and Biofilm Adhesion of the Pathogenic FungusJournal of fungi (Basel, Switzerland) · 2020Article
- Scedosporium Cell Wall: From Carbohydrate-Containing Structures to Host-Pathogen Interactions.Mycopathologia · 2020Review
- Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway.Journal of fungi (Basel, Switzerland) · 2020Review
- Insights into the interaction of Scedosporium apiospermum, Scedosporium aurantiacum, Scedosporium minutisporum, and Lomentospora prolificans with lung epithelial cells.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- Antiviral activity of glucosylceramides isolated from Fusarium oxysporum against Tobacco mosaic virus infection.PloS one · 2020Article
- Sphingolipid biosynthetic pathway is crucial for growth, biofilm formation and membrane integrity ofFuture medicinal chemistry · 2019Article
- Structural Differences Influence Biological Properties of Glucosylceramides from Clinical and Environmental Isolates ofJournal of fungi (Basel, Switzerland) · 2019Article
- Membrane Sphingolipids Regulate the Fitness and Antifungal Protein Susceptibility ofFrontiers in microbiology · 2019Article
- Glucosylceramides FromFrontiers in microbiology · 2019Article
- Article
- Scedosporium apiospermum, Scedosporium aurantiacum, Scedosporium minutisporum and Lomentospora prolificans: a comparative study of surface molecules produced by conidial and germinated conidial cells.Memorias do Instituto Oswaldo Cruz · 2018Article
- An insight into new strategies to combat antifungal drug resistance.Drug design, development and therapy · 2018Review
- Sphingolipids as targets for treatment of fungal infections.Future medicinal chemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scedosporium apiospermum is an emerging fungal pathogen that causes both localized and disseminated infections in immunocompromised patients. Glucosylceramides (CMH, GlcCer) are the main neutral glycosphingolipids expressed in fungal cells. In this study, glucosylceramides (GlcCer) were extracted and purified in several chromatographic steps. Using high-performance thin layer chromatography (HPTLC) and electrospray ionization mass spectrometry (ESI-MS), N-2'-hydroxyhexadecanoyl-1-β-D-glucopyranosyl-9-methyl-4,8-sphingadienine was identified as the main GlcCer in S. apiospermum. A monoclonal antibody (Mab) against this molecule was used for indirect immunofluorescence experiments, which revealed that this CMH is present on the surface of the mycelial and conidial forms of S. apiospermum. Treatment of S. apiospermum conidia with the Mab significantly reduced fungal growth. In addition, the Mab also enhanced the phagocytosis and killing of S. apiospermum by murine cells. In vitro assays were performed to evaluate the CMHs for their cytotoxic activities against the mammalian cell lines L.929 and RAW, and an inhibitory effect on cell proliferation was observed. Synergistic in vitro interactions were observed between the Mab against GlcCer and both amphotericin B (AmB) and itraconazole. Because Scedosporium species develop drug resistance, the number of available antifungal drugs is limited; our data indicate that combining immunotherapy with the available drugs might be a viable treatment option. These results suggest that in S. apiospermum, GlcCer are most likely cell wall components that are targeted by antifungal antibodies, which directly inhibit fungal development and enhance macrophage function; furthermore, these results suggest the combined use of monoclonal antibodies against GlcCer and antifungal drugs for antifungal immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.